Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BOSTON SCIENTIFIC CORPBSX · Entity 1897 | EVP & President, MedSurg | February 28, 2018 | March 01, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BOSTON SCIENTIFIC CORP
Report date February 28, 2018 · Filed March 01, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 133,373 |
Last balance in matching sequence
After 2018-02-28 transaction · row 3
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
3 source rowsRow 1 · 2018-02-28 · Exercise / conversion · Acquired 5,413 · Balance 134,423 F1: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Row 2 · 2018-02-28 · Exercise / conversion · Acquired 2,443 · Balance 136,866 F1: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Row 3 · 2018-02-28 · Tax withholding · Disposed 3,493 · Balance 133,373 F2: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. |
| Deferred Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2018-02-28 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2018-02-28 · Exercise / conversion · Disposed 5,413 · Balance 0 F1: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F3: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 28, 2014, the first anniversary of the date of grant. |
| Deferred Stock UnitsSEC Table II · derivative / convertible security · Expires 2022-02-28 | Direct | 9,776 |
Reported balance
After 2018-02-28 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2018-02-28 · Exercise / conversion · Disposed 2,443 · Balance 9,776 F1: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F4: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 28, 2018, the first anniversary of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.
F2: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available.
F3: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 28, 2014, the first anniversary of the date of grant.
F4: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 28, 2018, the first anniversary of the date of grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 26, 2017 Filed Apr 27, 2017 20:10 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 34,773 | $12.52 | $435,357.96 |
DisclosureSEC source: 0001225208-17-008530 · doc4.xml · nonDerivative · entry 1 Phalen Michael P. · CIK 0001483882 · EVP & President, MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,692 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| March 29, 2017 Filed Mar 30, 2017 20:37 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionStock Option (Right to Buy) · Derivative | 46,500 | $0.00 Strike: $7.16 | $0.00 |
DisclosureSEC source: 0001225208-17-007048 · doc4.xml · derivative · entry 4 Phalen Michael P. · CIK 0001483882 · EVP & President, MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,835 Underlying: Common Stock · 46,500 shares Expires 2021-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan. F4 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 28, 2012, the first anniversary of the grant. Read SEC document |
| March 29, 2017 Filed Mar 30, 2017 20:37 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | SaleCommon Stock | 79,045 | $24.55 | $1,940,341.33 |
DisclosureSEC source: 0001225208-17-007048 · doc4.xml · nonDerivative · entry 2 Phalen Michael P. · CIK 0001483882 · EVP & President, MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,919 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| March 29, 2017 Filed Mar 30, 2017 20:37 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 46,500 | $7.16 | $332,940.00 |
DisclosureSEC source: 0001225208-17-007048 · doc4.xml · nonDerivative · entry 1 Phalen Michael P. · CIK 0001483882 · EVP & President, MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,964 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 01:56 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantStock Option (Right to Buy) · Derivative | 39,525 | $0.00 Strike: $24.55 | $0.00 |
DisclosureSEC source: 0001225208-17-005155 · doc4.xml · derivative · entry 8 Phalen Michael P. · CIK 0001483882 · EVP & President, MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,525 Underlying: Common Stock · 39,525 shares Expires 2027-02-28 F10 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 28, 2018, the first anniversary of the date of grant. Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 01:56 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantPerformance Share Units · Derivative | 14,059 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-005155 · doc4.xml · derivative · entry 7 Phalen Michael P. · CIK 0001483882 · EVP & President, MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,059 Underlying: Common Stock · 14,059 shares Expires 2018-12-31 F8 · derivative.exercise_price: Each performance share unit represents the Company's commitment to issue one share of Boston Scientific common stock. F9 · shares: On February 22, 2016, the reporting person was awarded a target number of performance share units under the Company's 2016 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person based on the Company's 2016 adjusted free cash flow measured against its 2016 financial plan over the one-year performance period ending December 31, 2016 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 28, 2017, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2018. F9 · derivative.exercise_date: On February 22, 2016, the reporting person was awarded a target number of performance share units under the Company's 2016 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person based on the Company's 2016 adjusted free cash flow measured against its 2016 financial plan over the one-year performance period ending December 31, 2016 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 28, 2017, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2018. F9 · derivative.expiration_date: On February 22, 2016, the reporting person was awarded a target number of performance share units under the Company's 2016 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person based on the Company's 2016 adjusted free cash flow measured against its 2016 financial plan over the one-year performance period ending December 31, 2016 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 28, 2017, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2018. F9 · balance_after: On February 22, 2016, the reporting person was awarded a target number of performance share units under the Company's 2016 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person based on the Company's 2016 adjusted free cash flow measured against its 2016 financial plan over the one-year performance period ending December 31, 2016 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 28, 2017, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2018. Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 01:56 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantDeferred Stock Units · Derivative | 12,219 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-005155 · doc4.xml · derivative · entry 6 Phalen Michael P. · CIK 0001483882 · EVP & President, MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,219 Underlying: Common Stock · 12,219 shares Expires 2022-02-28 F3 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F7 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 28, 2018, the first anniversary of the date of grant. F7 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 28, 2018, the first anniversary of the date of grant. Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 01:56 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionDeferred Stock Units · Derivative | 5,413 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-005155 · doc4.xml · derivative · entry 5 Phalen Michael P. · CIK 0001483882 · EVP & President, MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,413 Underlying: Common Stock · 5,413 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F5 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 28, 2014, the first anniversary of the date of grant. F5 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 28, 2014, the first anniversary of the date of grant. F6 · balance_after: Reflects multiple DSU awards with independent vesting schedules. Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 01:56 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 17,214 | $24.55 | $422,603.70 |
DisclosureSEC source: 0001225208-17-005155 · doc4.xml · nonDerivative · entry 3 Phalen Michael P. · CIK 0001483882 · EVP & President, MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,464 F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 01:56 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 5,413 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-005155 · doc4.xml · nonDerivative · entry 2 Phalen Michael P. · CIK 0001483882 · EVP & President, MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 151,678 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 01:56 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantCommon Stock | 34,402 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-005155 · doc4.xml · nonDerivative · entry 1 Phalen Michael P. · CIK 0001483882 · EVP & President, MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,265 F1 · shares: On February 24, 2014, the reporting person was awarded a target number of performance share units under the Company's 2014 Total Shareholder Return Performance Share Program, the actual number of which to be earned by the reporting person was based on the Company's total shareholder return performance percentile relative to that of the other companies in the S&P 500 Healthcare Index over the three annual performance cycles comprising the three-year period ended December 31, 2016 and was subject to the completion of the concurrent three-year individual service period. On February 28, 2017, the number of the target performance share units as to which the performance criteria had been satisfied was determined and the individual service period was satisfied. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| February 27, 2017 Filed Feb 28, 2017 21:46 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionDeferred Stock Units · Derivative | 6,370 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-004926 · doc4.xml · derivative · entry 4 Phalen Michael P. · CIK 0001483882 · EVP & President, MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,826 Underlying: Common Stock · 6,370 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F4 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 27, 2013, the first anniversary of the date of grant. F4 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 27, 2013, the first anniversary of the date of grant. F5 · balance_after: Reflects multiple DSU awards with independent vesting schedules. Read SEC document |
| February 27, 2017 Filed Feb 28, 2017 21:46 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 2,068 | $24.81 | $51,307.08 |
DisclosureSEC source: 0001225208-17-004926 · doc4.xml · nonDerivative · entry 2 Phalen Michael P. · CIK 0001483882 · EVP & President, MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,863 F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| February 27, 2017 Filed Feb 28, 2017 21:46 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 6,370 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-004926 · doc4.xml · nonDerivative · entry 1 Phalen Michael P. · CIK 0001483882 · EVP & President, MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,931 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| February 24, 2017 Filed Feb 27, 2017 21:30 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionDeferred Stock Units · Derivative | 3,440 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-004742 · doc4.xml · derivative · entry 4 Phalen Michael P. · CIK 0001483882 · EVP & President, MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,881 Underlying: Common Stock · 3,440 shares Expires 2019-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F4 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 24, 2015, the first anniversary of the date of grant. F4 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 24, 2015, the first anniversary of the date of grant. Read SEC document |
| February 24, 2017 Filed Feb 27, 2017 21:30 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 1,117 | $24.78 | $27,679.26 |
DisclosureSEC source: 0001225208-17-004742 · doc4.xml · nonDerivative · entry 2 Phalen Michael P. · CIK 0001483882 · EVP & President, MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,561 F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| February 24, 2017 Filed Feb 27, 2017 21:30 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 3,440 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-004742 · doc4.xml · nonDerivative · entry 1 Phalen Michael P. · CIK 0001483882 · EVP & President, MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,678 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| February 23, 2017 Filed Feb 24, 2017 22:22 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionDeferred Stock Units · Derivative | 2,452 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-004608 · doc4.xml · derivative · entry 4 Phalen Michael P. · CIK 0001483882 · EVP & President, MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,358 Underlying: Common Stock · 2,452 shares Expires 2020-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F4 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 23, 2016, the first anniversary of the date of grant. F4 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 23, 2016, the first anniversary of the date of grant. Read SEC document |
| February 23, 2017 Filed Feb 24, 2017 22:22 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 796 | $24.48 | $19,486.08 |
DisclosureSEC source: 0001225208-17-004608 · doc4.xml · nonDerivative · entry 2 Phalen Michael P. · CIK 0001483882 · EVP & President, MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,238 F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| February 23, 2017 Filed Feb 24, 2017 22:22 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 2,452 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-004608 · doc4.xml · nonDerivative · entry 1 Phalen Michael P. · CIK 0001483882 · EVP & President, MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,034 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| February 22, 2017 Filed Feb 23, 2017 23:41 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionDeferred Stock Units · Derivative | 2,462 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-004434 · doc4.xml · derivative · entry 4 Phalen Michael P. · CIK 0001483882 · EVP & President, MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,849 Underlying: Common Stock · 2,462 shares Expires 2021-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F4 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 22, 2017, the first anniversary of the date of grant. F4 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 22, 2017, the first anniversary of the date of grant. Read SEC document |
| February 22, 2017 Filed Feb 23, 2017 23:41 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 799 | $25.16 | $20,102.84 |
DisclosureSEC source: 0001225208-17-004434 · doc4.xml · nonDerivative · entry 2 Phalen Michael P. · CIK 0001483882 · EVP & President, MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,582 F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| February 22, 2017 Filed Feb 23, 2017 23:41 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 2,462 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-004434 · doc4.xml · nonDerivative · entry 1 Phalen Michael P. · CIK 0001483882 · EVP & President, MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,381 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| January 01, 2017 Filed Jan 4, 2017 21:40 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionPerformance Share Units · Derivative | 17,510 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-000412 · doc4.xml · derivative · entry 4 Phalen Michael P. · CIK 0001483882 · EVP & President, MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,510 shares Expires 2016-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each performance share unit represents the Company's commitment to issue one share of Boston Scientific common stock. F1 · shares: On February 24, 2014, the reporting person was awarded a target number of performance share units under the Company's 2014 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person based on the Company's 2014 adjusted free cash flow measured against its 2014 financial plan over the one-year performance period ending December 31, 2014 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 23, 2015, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon the completion of the individual service period that ended on December 31, 2016. F1 · derivative.exercise_date: On February 24, 2014, the reporting person was awarded a target number of performance share units under the Company's 2014 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person based on the Company's 2014 adjusted free cash flow measured against its 2014 financial plan over the one-year performance period ending December 31, 2014 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 23, 2015, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon the completion of the individual service period that ended on December 31, 2016. F1 · derivative.expiration_date: On February 24, 2014, the reporting person was awarded a target number of performance share units under the Company's 2014 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person based on the Company's 2014 adjusted free cash flow measured against its 2014 financial plan over the one-year performance period ending December 31, 2014 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 23, 2015, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon the completion of the individual service period that ended on December 31, 2016. Read SEC document |
| January 01, 2017 Filed Jan 4, 2017 21:40 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 5,964 | $21.63 | $129,001.32 |
DisclosureSEC source: 0001225208-17-000412 · doc4.xml · nonDerivative · entry 2 Phalen Michael P. · CIK 0001483882 · EVP & President, MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,632 F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| January 01, 2017 Filed Jan 4, 2017 21:40 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 17,510 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-000412 · doc4.xml · nonDerivative · entry 1 Phalen Michael P. · CIK 0001483882 · EVP & President, MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,596 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: On February 24, 2014, the reporting person was awarded a target number of performance share units under the Company's 2014 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person based on the Company's 2014 adjusted free cash flow measured against its 2014 financial plan over the one-year performance period ending December 31, 2014 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 23, 2015, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon the completion of the individual service period that ended on December 31, 2016. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.